My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Buy Ruxolitinib Cream Online

Buy Ruxolitinib Cream Online

Ruxolitinib Cream

A young woman who had no scalp or eyebrow hair for years has grown a full head of hair after using a cream devised by researchers at the Yale School of Medicine. The 17-year-old patient had alopecia areata, a disfiguring autoimmune disease that affects tens of millions of people worldwide and has limited treatment options. The disorder may cause spotty hair loss or complete loss of scalp hair, eyebrows, eyelashes, and all other body hair. The patient in this study, which was published in JAMA Dermatology, had tried multiple treatments without success.

To treat the condition, Dr. Brett King, assistant professor of dermatology, and his colleagues devised a topical formulation of an oral medication used to treat bone marrow diseases. The drug, ruxolitinib (Jakafi, Incyte Corporation), belongs to a class of medications called Janus kinase (JAK) inhibitors, which alter the immune system. King had previously used another oral JAK inhibitor, tofacitinib (Xeljanz, Pfizer), to restore hair in a male patient with alopecia universalis in 2014, and other researchers have shown that oral ruxolitinib also restores hair in this condition.

‘Where Can I Get Ruxolitinib Cream for Alopecia Areata From?’

It is currently being investigated as part of clinical trials exploring whether or not a number of drugs known as JAK inhibitors are suitable to treat hair loss from autoimmune conditions. Researchers are testing them for both safety and efficacy on participants with Alopecia Areata as well as the more severe Alopecia Totalis (no head hair) and Alopecia Universalis (complete lack of hair from head to toe). Results so far have been encouraging, however, until the studies have passed all the rigorous test procedures needed to ensure they are safe to use, these drugs will not be made available to prescribe or purchase.

Yale Study Shows Topical Ruxolitinib Grows Hair

A young woman who had no scalp or eyebrow hair for years now enjoys a full mane after using a novel cream devised by researchers at Yale School of Medicine. The 17-year-old patient suffered from alopecia areata, a disfiguring autoimmune disease that affects tens of millions of people worldwide and has limited treatment options. Alopecia areata may cause spotty hair loss or complete loss of scalp hair, eyebrows, eyelashes and all other body hair.

The patient in this study, published December 9 in JAMA Dermatology, had tried multiple treatments with no success. To treat the condition, Dr. Brett King, assistant professor dermatology, and his co-authors, Dr. Brittany Craiglow and Daniel Tavares, devised a topical formulation of an oral medication used to treat bone marrow diseases.

Topical Ruxolitinib for the Treatment of Alopecia Universalis

Alopecia areata and variants alopecia totalis and alopecia universalis are common conditions for which treatment options are limited. Oral Janus kinase (JAK) inhibitors have recently been shown to be effective for the treatment of these disorders. There are, however, risks for serious adverse effects with systemic therapy that may be avoided if topical therapy were an option.

Discussion

To our knowledge, this is the first report of successful treatment of alopecia universalis with a topical JAK inhibitor. While additional studies will be needed to confirm the efficacy, further explore the safety and tolerability, and determine optimal concentrations of topical ruxolitinib and other topical JAK inhibitors for alopecia areata and variants, the results in this case are promising. Although uncommon, serious adverse effects including cancer have been reported in patients taking oral JAK inhibitors.

Know More About This Medicine and Buy Now : MedyPharma.com

 

 

Loading...